Mechanisms linking the renin-angiotensin system, obesity, and breast cancer
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Obesity is a complex disease and a global epidemic. It is a risk factor for other chronic diseases including breast cancer, especially in women after menopause. Diverse etiologies underlie the relationship between obesity and breast cancer. Adipose tissue is in part responsible for these interactions. In obesity, adipose tissue undergoes several metabolic dysregulations resulting in the secretion of many pro-inflammatory cytokines, growth factors, and hormones which in turn, can promote tumor microenvironment (TME) formation and cancer progression within the breast tissue. Angiotensin II (Ang II) is a well-known hypertensive hormone produced systemically and locally by the renin-angiotensin system (RAS). Activation of this system in obesity is a potential contributor to local and systemic inflammation in breast adipose tissue. Ang II actions are primarily mediated through binding to its two receptors, type 1 (AT1R) and type 2 (AT2R). RAS inhibitors include angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) which are currently prescribed as safe antihypertensive therapies. Recent studies have explored the potential use of ACE-I and ARBs in breast cancer patients as anti-tumor agents. Therefore, it is vital to understand the role of RAS in breast cancer and identify mechanisms of Ang II and RAS inhibitors in the TME and in obesity and breast cancer crosstalk. In this review, we performed a detailed analysis and discussed mechanisms of Ang II-AT1R interactions in breast cancer with emphasis on obesity-associated breast cancer. We further summarized recent in vitro, in vivo and human studies that used ACE-I/ARB interventions to improve breast cancer outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Chronic Inflammation in Obesity and the Metabolic Syndrome
Monteiro, R., & Azevedo, I. (2010) · Mediators of Inflammation · doi:10.1155/2010/289645 · Cited by 1,186 · cited 1×
“Increased adipose hypertrophy due to obesity is positively correlated with recruitment of inflammatory immune cells to adipose tissue (Monteiro & Azevedo 2010).”
BackgroundRegulation of hypoxia-inducible factor-1α by NF-κB
van Uden, P., Kenneth, N. S., & Rocha, S. (2008) · Biochemical Journal · doi:10.1042/bj20080476 · Cited by 729
Physiology and Pathophysiology of the Adipose Tissue Renin-Angiotensin System
Engeli, S., Negrel, R., & Sharma, A. M. (2000) · Hypertension · doi:10.1161/01.hyp.35.6.1270 · Cited by 475
Interleukin-8 and the chemokine family
Baggiolini, M., Loetscher, P., & Moser, B. (1995) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(94)00088-6 · Cited by 400
Walter, M., Liang, S., Ghosh, S., Hornsby, P. J., & Li, R. (2009) · Oncogene · doi:10.1038/onc.2009.130 · Cited by 312
Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System
Scheen, A. J. (2004) · Drugs · doi:10.2165/00003495-200464220-00004 · Cited by 293 · cited 1×
“Interestingly, RAS inhibitors have been used to prevent diabetes (Scheen 2004).”
BackgroundAromatase, breast cancer and obesity: a complex interaction
Bulun, S. E., Chen, D., Moy, I., Brooks, D. C., & Zhao, H. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.10.003 · Cited by 224
Incio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222
Cited by
Metabolic syndrome-related kidney injury: a review and update
Lin, L., Tan, W., Pan, X., Tian, E., Wu, Z., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.904001 · Cited by 139
Renin–angiotensin system: Basic and clinical aspects—A general perspective
Vargas Vargas, R. A., Varela Millán, J. M., & Fajardo Bonilla, E. (2022) · Endocrinología, Diabetes y Nutrición (English ed.) · doi:10.1016/j.endien.2022.01.005 · Cited by 51
Yeh, J.-J., Lai, J.-N., Lin, C.-L., Hsu, C.-Y., & Kao, C.-H. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047039 · Cited by 16
“20 36 These comorbidities aggravated the overexpression of EGFR signalling and VEGF, which are associated with cancer formation among patients with ILD and pulmonary fibrosis.”
Metadata
- Authors
- Rasha, F., Ramalingam, L., Gollahon, L., Rahman, R. L., Rahman, S. M., Menikdiwela, K., & Moustaid-Moussa, N.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2019-12
- Volume
- 26
- Issue
- 12
- Pages
- R653-R672
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2974878150
- Cited by
- 62
- References
- 11
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.